Targeting the PD-1/PD-L1 axis has become a central focus in cancer immunotherapy, with monoclonal antibodies (mAbs) such as pembrolizumab and nivolumab receiving FDA approval since 2014 (54, 55). Here, CD274 is linked to cancer.